Zacks Research Increases Earnings Estimates for Omnicell

Omnicell, Inc. (NASDAQ:OMCL) – Equities researchers at Zacks Research lifted their FY2027 earnings per share estimates for shares of Omnicell in a research report issued on Thursday, March 5th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.13 for the year, up from their previous estimate of $1.11. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q4 2027 earnings at $0.30 EPS and FY2028 earnings at $1.44 EPS.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The company had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. During the same quarter in the previous year, the business posted $0.60 earnings per share. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS.

Several other equities research analysts also recently issued reports on the company. Wells Fargo & Company increased their price objective on Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Wall Street Zen lowered Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a research note on Wednesday, February 4th. KeyCorp raised Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 target price on the stock in a report on Wednesday, January 7th. Finally, Piper Sandler restated an “overweight” rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $54.50.

Omnicell Trading Up 1.7%

Omnicell stock opened at $42.25 on Friday. The firm’s 50 day moving average price is $44.71 and its two-hundred day moving average price is $38.20. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 1,056.51, a price-to-earnings-growth ratio of 1.49 and a beta of 0.79. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43. Omnicell has a 1 year low of $22.66 and a 1 year high of $55.00.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently made changes to their positions in OMCL. Raymond James Financial Inc. acquired a new stake in shares of Omnicell in the 2nd quarter valued at about $26,000. First Horizon Corp bought a new stake in Omnicell in the 3rd quarter valued at about $31,000. Farther Finance Advisors LLC lifted its holdings in Omnicell by 784.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock worth $36,000 after purchasing an additional 1,036 shares in the last quarter. Clearstead Advisors LLC boosted its position in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after acquiring an additional 1,218 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in Omnicell in the 4th quarter worth approximately $58,000. Institutional investors own 97.70% of the company’s stock.

Insider Activity at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the transaction, the executive vice president directly owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.52% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.